Tetragon Financial Group — Tetragon maintains its investing pace

Tetragon Financial Group (LSE: TFG)

Last close As at 23/12/2024

USD12.70

0.00 (0.00%)

Market capitalisation

USD1,775m

DISCLAIMER

Please read the Terms of Use below carefully.

You must accept these terms before you can proceed to content on Tetragon Financial Group.

Restrictions on Ownership by US Persons

Tetragon’s shares have not been and will not be registered under the United States Securities Act of 1933. Consequently, Tetragon shares may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, ‘US persons’ as defined in Regulation S under the Securities Act absent registration or an exemption from registration under the Securities Act. No public offering of any Tetragon shares is being, or has been, made in the United States.

In addition, Tetragon has not been and will not be registered under the United States Investment Company Act of 1940. Direct or indirect beneficial ownership of securities issued by Tetragon to any US person who is not a ‘qualified purchaser’ as defined in the Investment Company Act and applicable rules thereunder is prohibited. Under Tetragon’s Articles of Incorporation, the directors of Tetragon may in certain circumstances compel the transfer of any Tetragon shares owned directly or beneficially by any person who is not a ‘qualified purchaser’.

Ownership by Persons in Europe

Tetragon’s non-voting shares are not intended for European retail investors. Tetragon anticipates that its typical investors will be institutional and professional investors who wish to invest for the long term and who have experience in investing in financial markets and collective investment

undertakings and are capable themselves of evaluating the merits and risks of Tetragon shares and who have sufficient resources both to invest in potentially illiquid securities and to be able to bear any losses (which may equal the whole amount invested) that may result from the investment.

More on Tetragon Financial Group

View All

Latest from the Investment Companies sector

View All Investment Companies content

Research: Healthcare

Cereno Scientific — CS1 shines in Phase IIa PAH trial

Cereno Scientific has reported positive top-line results for the Phase IIa CS1-003 trial, which evaluated the HDAC inhibitor CS1 in pulmonary arterial hypertension (PAH). The primary endpoint of safety and tolerability was met and, importantly, CS1 delivered encouraging results on exploratory efficacy measures, creating a strong foundation for the next steps of clinical development, in our view. The recently signed agreement with medical technology company Fluidda to visualise the impact of CS1 on the reverse remodelling of pulmonary vessels is another positive step and could bolster the data package for the candidate. With the recent preclinical data on CS014, Cereno now has two HDAC inhibitors in its portfolio with disease-modifying potential and we expect this to influence discussions with regulators, as well as potential partners. As management is planning a potentially pivotal Phase IIb/III trial, we raise our probability of success for CS1 to 40% (from 25%), resulting in our valuation for Cereno upgrading to SEK13.9/share from SEK9.1/share.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free